Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma
Clinical trial NCT07156019 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07156019
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-01
- Primary completion
- 2026-12-01
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.